Translating Causation To Treatment - Reviewing The Microbiome's Role In Drug Development

APPLICATIONS IN THERAPEUTICS, NUTRITION AND DIAGNOSTICS

7.50

Registration & Morning Coffee

8.50

Chairperson Opening Remarks

Shingo Arioka
Research Manager
Shionogi

Live-BioTherapeutic Discovery, Clinical Development & Manufacturing

Session Purpose:

We have begun to develop more characterised therapeutic candidates based on single-strain organisms or a precise consortia of organisms, termed LBPs. LBPs have the promise of providing the same efficacy as FMTs but with a more characterised, and therefore predictable safety profile. Currently, there has been a growing body of the use of LBPs across a variety of disease phenotypes, including IBD, Diabetes, Cancer, Autism and many more. The purpose of this theme will be to review cutting-edge case studies on the use of LBPs to reverse disease phenotypes driven by an unwanted dysbiosis in the human microbiome.

9.00

Developing Microbiome into a Medicine

Jisoo Pae
Founder and CEO
Genome and Company

9.30

Bacillus Spore-Based Oral Biotherapeutics

 

 

Jae-Gu Pan
CTO
GenoFocus

10.00

GI 310, a Novel Long-Acting Ige Trap-Fc Fusion Protein that Elicits Therapeutic Synergy in Combination with a Microbiome Agent for the Treatment of Food Allergy

Yang Bo Gie
CSO
GI Innovation

10.30

The Asian Gut Microbiome: A New Therapeutics Discovery Opportunity

 

 

Jonathan Krive
CEO
AsiaBiome

11.00

Morning Coffee & Refreshments Break

11.30

AI Approaches to Microbiome-Based Drug Development in China

Yiming Yin
VP, Research & Product Development
XBiome

Microbiome-Based Biomarker Discovery – Patient Stratification Tools
Session

Session Purpose:

As molecular biomarkers continue to become an important component to diagnose disease and predicting response to treatment, the human microbiome has become a rich source for novel biomarker discovery across broad range of disease phenotypes. The purpose of this theme will be to review current efforts in biomarker discovery and applications within the drug development and diagnostic industry.

12.00

Development of Endometrial Microbiome Testing for
Reproductive Health

Yoshiyuki Sakuraba
CEO
Varinos

12.30

Lunch Break & Networking

POLICY, REGULATION & INVESTMENT

Session Purpose:

Since the establishment of the Human Microbiome Project (HMP) and MetaHIT in 2008, there have been a growing number of global initiatives funded by government, academia and private organisations that look to accelerate translational microbiome research by exchanging methodologies, promoting standardisation and exchange ideas for the future applicability of this cutting-edge science. The purpose of this theme will be to highlight the successful efforts that are happening in the Asia-Pacific region as it relates to cooperating on microbiome-based research and the outcomes of these partnerships.

13.30

Introduction and Overview to the Korea Gut Microbiome Society Initiatives

Wang-Jun Lee MD
CEO & Chairman
Myongji Hospital

14.00

Introduction of the Asian Microbiome Project: Study on Correlation among Diet, Gut Microbiota and Overall Health of Asian People

 

 

Lee Yuan Kun
Associate Professor
National University of
Singapore

Regulatory Frameworks for Microbiome-Based Products

Session Purpose:

As microbiome-based therapies constitute a novel paradigm in modern medicine, a robust regulatory framework that
addresses key safety and CMC issues should be evaluated for safe implementation of these treatments to patients in need.
Despite the rise in notoriety across the pharmaceutical industry, only a few regulatory agencies have provided clarity over the
regulatory hurdles when developing a microbiome-based therapeutic. The purpose of this theme will be to outline how leading
regulatory bodies in Asia and Internationally are currently reviewing microbiome candidates whilst highlighting successful IND
applications for emerging and well established microbiome companies.

14.30

Current Regulation of Microbiome-Based Therapeutics in Korea

Suenie Park
Professor
Hallym University

15.00

Chairperson Closing Remarks

15.10

Close of Inaugural Microbiome Movement - Drug Development & Nutrition Summit